Shots:

• Janssen and Resolution Bioscience develops Resolution’s HRD liquid biopsy test as a companion diagnostic for Janssen’s Niraparib- being investigated for the treatment of metastatic castration-resistant prostate cancer
• The Resolution HRD assay will allow Janssen to identify patients with prostate cancer who may benefit from Niraparib therapy. In 2016- Janssen got exclusive WW license from Tesaro for Niraparib in prostate cancer
• The Resolution’s liquid biopsy test detects HRD mutations & gene deletions- being evaluated in P-II & P-III studies of Niraparib in PC and has received FDA’s BT designation on May 30- 2019

Ref: Resolution Bio | Image: Janssen